Skip to main content
SpringerLink
Log in

Clinical Pharmacokinetics of Almotriptan, a Serotonin 5-HT1B/1D Receptor Agonist for the Treatment of Migraine

  • Review Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

The pharmacokinetics of almotriptan are linear over a range of oral doses up to 200mg in healthy volunteers. The compound has a half-life of approximately 3 hours. Almotriptan is well absorbed after oral administration and the mean absolute bioavailability is 69.1%. Maximal plasma concentrations are achieved between 1.5 and 4 hours after dose administration; however, within 1 hour after administration, plasma concentrations are approximately 68% of the value at 3 hours after administration. Food does not significantly affect almotriptan absorption.

Almotriptan is not highly protein bound and is extensively distributed in the body. Approximately 50% of an almotriptan dose is excreted unchanged in the urine; this is the predominant single mechanism of elimination. Renal clearance is mediated, in part, through active tubular secretion, while the balance of the almotriptan dose is metabolised to inactive compounds. The predominant route of metabolism is via monoamine oxidase-A, and cytochrome P450 (CYP) mediated oxidation (via CYP3A4 and CYP2D6) occurs to a minor extent.

Almotriptan clearance is moderately reduced in elderly subjects, but the magnitude of this effect does not warrant a dose reduction. Sex has no significant effect on almotriptan pharmacokinetics. Almotriptan pharmacokinetic parameters do not differ between adolescents and adults, and absorption is not affected during a migraine attack. As expected, renal dysfunction results in reduced clearance of almotriptan. Patients with moderate-to-severe renal dysfunction should use the lowest dose of almotriptan and the total daily dose should not exceed 12.5mg. Similar dosage recommendations are valid for patients with hepatic impairment, based on the clearance mechanisms for almotriptan.

Drug-drug interaction studies were conducted between almotriptan and the following compounds: fluoxetine, moclobemide, propranolol, verapamil and ketoconazole. No significant pharmacokinetic or pharmacodynamic interactions with almotriptan were observed for fluoxetine or propranolol. Almotriptan clearance was reduced, to a modest degree, by moclobemide and verapamil, which was consistent with the contribution of monoamine oxidase-A and CYP3A4 to the metabolic clearance of almotriptan. Although ketoconazole has a greater effect on almotriptan clearance than verapamil, no dosage adjustment is required when almotriptan is given with these drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Table II
Table III

Similar content being viewed by others

References

  1. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000 Dec; 60(6): 1259–87

    Article  PubMed  CAS  Google Scholar 

  2. Goadsby PJ. The pharmacology of headache. Prog Neurobiol 2000 Dec; 62(5): 509–25

    Article  PubMed  CAS  Google Scholar 

  3. Cabarrocas X, Zayas JM, on behalf of the Almotriptan Oral Study Group. Efficacy data on oral almotriptan, a novel 5-HT1B/1D agonist. 40th Annual Scientific Meeting of the American Association for the Study of Headache; 1998 Jun 26–28; San Francisco

  4. Dodick DW. Oral almotriptan in the treatment of migraine: safety and tolerability. Headache 2001 May; 41(5): 449–55

    Article  PubMed  CAS  Google Scholar 

  5. Jhee SS, Shiovitz T, Crawford AW, et al. Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin Pharmacokinet 2001; 40(3): 189–205

    Article  PubMed  CAS  Google Scholar 

  6. Diener HC, Limmroth V. Acute management of migraine: triptans and beyond. Curr Opin Neurol 1999 Jun; 12(3): 261–7

    Article  PubMed  CAS  Google Scholar 

  7. Dodick DW, Silberstein S, Dahlof CG. Is there a preferred triptan? Headache 2002 Jan; 42(1): 1–7

    Article  PubMed  Google Scholar 

  8. Cabarrocas X, Salvà M. Pharmacokinetic and metabolic data on almotriptan, a new antimigraine drug [abstract]. Cephalalgia 1997 May; 17(3): 421

    Google Scholar 

  9. Garcia E, Cabarrocas X, Jansat JM, et al. A clinical trial to determine the lack of food interaction on the bioavailability of almotriptan, a new 5-HT1B/1D agonist, in healthy volunteers. 40th Annuual Scientific Meeting of the American Association for the Study of Headache; 1998 Jun 26–28; San Francisco

  10. Cabarrocas X, Warrington SJ, Jansat JM, et al. Pharmacokinetics and tolerability of oral almotriptan in the elderly [poster]. Ninth Congress of the International Headache Society; 1999 Jun 22–26; Amsterdam

  11. Cabarrocas X, Fernandez FJ, Popescu G, et al. The pharmacokinetics and tolerability of almotriptan in renal impairment [abstract]. Headache 1999 May; 39(5): 346

    Google Scholar 

  12. Salvà M, Palacios JM, Martinez-Tobed A. Metabolism of the novel anti-migraine compound almotriptan (LAS 31416) in humans [abstract]. 6th European International Society for the Study of Xenobiotics (ISSX) meeting; 1997 Jun 30–Jul 3; Gothenberg

  13. Jansat JM, Costa J, Salvà P, et al. Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers. J Clin Pharmacol 2002 Dec; 42(12): 1303–10

    Article  PubMed  CAS  Google Scholar 

  14. Boyce M, Dunn K, Warrington S. Hemodynamic and electrocardiographic effects of almotriptan in healthy volunteers. J Cardiovasc Pharmacol 2001 Mar; 37(3): 280–9

    Article  PubMed  CAS  Google Scholar 

  15. Fleishaker JC, Ryan KK, Carel BJ, et al. Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. J Clin Pharmacol 2001 Feb; 41(2): 217–23

    Article  PubMed  CAS  Google Scholar 

  16. Fleishaker JC, Ryan KK, Jansat JM, et al. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. Br J Clin Pharmacol 2001 May; 51(5): 437–41

    Article  PubMed  CAS  Google Scholar 

  17. Fleishaker JC, Sisson TA, Carel BJ, et al. Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers. Cephalalgia 2001 Feb; 21(1): 61–5

    Article  PubMed  CAS  Google Scholar 

  18. Fleishaker JC, Sisson TA, Carel BJ, et al. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. Clin Pharmacol Ther 2000 May; 67(5): 498–503

    Article  PubMed  CAS  Google Scholar 

  19. Fleishaker JC, McEnroe JD, Azie NE, et al. Cardiovascular effect of almotriptan in treated hypertensive patients. Clin Pharmacol Ther 2002 Mar; 71(3): 169–75

    Article  PubMed  CAS  Google Scholar 

  20. Fleishaker JC, Herman BD, Carel BJ, et al. Interaction between ketoconazole and almotriptan in healthy volunteers. J Clin Pharmacol 2003 Apr; 43(4): 423–7

    Article  PubMed  CAS  Google Scholar 

  21. Cabarrocas X, Jansat JM, Ferrer P, et al. Pharmacokinetics of oral almotriptan during and outside a migraine attack [abstract]. Cephalalgia 2000 Jun; 20(4): 417

    Google Scholar 

  22. Baldwin JR, Fleishaker JC, Azie NE, et al. A comparison of the pharmacokinetics and tolerability of the anti-migraine compound almotriptan in healthy adolescents and adults. Cephalalgia 2004; 24(4): 288–92

    Article  PubMed  CAS  Google Scholar 

  23. Gras J, Llenas J, Jansat JM, et al. Almotriptan, a new anti-migraine agent: a review. CNS Drug Rev 2002; 8(3): 217–34

    Article  PubMed  CAS  Google Scholar 

  24. Buchan P, Keywwo C, Wade A, et al. Clinical pharmacokinetics of frovatriptan. Headache 2002 Apr; 42 Suppl. 2: S54–62

    Article  PubMed  Google Scholar 

  25. Moore KHP, Leese PT, McNeal S, et al. The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteers. Clin Ther 2002 Apr; 24(4): 583–94

    Article  PubMed  CAS  Google Scholar 

  26. Palacios JM, Rabasseda X, Castañer J. Almotriptan. Drugs Fut 1999; 24(4): 367–74

    Article  CAS  Google Scholar 

  27. Keam SJ, Goa KL, Figgitt DP. Almotriptan: a review of its use in migraine. Drugs 2002; 62(2): 387–414

    Article  PubMed  CAS  Google Scholar 

  28. Physician’s desk reference. Montvale (NJ): Medical Economics Inc., 2002

  29. Gillotin C, Bagnis C, Mamet JP, et al. No need to adjust the dose of 311C90 (zolmitriptan), a novel anti-migraine treatment, in patients with renal failure not requiring dialysis. Int J Clin Pharm Ther 1997 Nov; 35(11): 522–6

    CAS  Google Scholar 

  30. Almotriptan: product monograph. Barcelona: Almirall Prodesfarma, 2000 Jul

  31. Peck RW, Seaber EJ, Dixon RM, et al. The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women. Clin Pharmacol Ther 1998 Mar; 63(3): 342–53

    Article  PubMed  CAS  Google Scholar 

  32. Lee Y, Conroy JA, Stepanavage ME, et al. Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. Br J Clin Pharmacol 1999 Apr; 47(4): 373–8

    Article  PubMed  CAS  Google Scholar 

  33. Musson DG, Birk KL, Panebianco DL, et al. Pharmacokinetics of rizatriptan in healthy elderly subjects. Int J Clin Pharmacol Ther 2001 Oct; 39(10): 447–52

    PubMed  CAS  Google Scholar 

  34. Ramadan NM, Schultz LL, Gilkey SJ. Migraine prophylactic drugs: proof of efficacy, utilization and cost. Cephalalgia 1997 Apr; 17(2): 73–80

    Article  PubMed  CAS  Google Scholar 

  35. Rolan P. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90). Cephalalgia 1997; 17 Suppl. 18: 21–7

    PubMed  Google Scholar 

  36. Goldberg MR, Lowry RC, Musson DG, et al. Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine. J Clin Pharmacol 1999 Feb; 39(2): 192–9

    Article  PubMed  CAS  Google Scholar 

  37. Scott AK, Walley T, Breckenridge AM, et al. Lack of an interaction between propranolol and sumatriptan. Br J Clin Pharmacol 1991 Nov; 32(5): 581–4

    Article  PubMed  CAS  Google Scholar 

  38. Buchan P, Wade A, Ward C, et al. Frovatriptan: a review of drug-drug interactions. Headache 2002 Apr; 42 Suppl. 2: S63–73

    Article  PubMed  Google Scholar 

  39. Peck RW, Seaber EJ, Dixon R, et al. The interaction between propranolol and the novel antimigraine agent zolmitriptan. Br J Clin Pharmacol 1997 Dec; 44(6): 595–9

    Article  PubMed  CAS  Google Scholar 

  40. Goldberg MR, Sciberras D, De Smet M, et al. Influence of β-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist: differential effects of propranolol, nadolol and metoprolol. Br J Clin Pharmacol 2001 Jul; 52(1): 69–76

    Article  PubMed  CAS  Google Scholar 

  41. Christensen ML, Eades SK, Fuseau E, et al. Pharmacokinetics of naratriptan in adolescent subjects with a history of migraine. J Clin Pharmacol 2001 Feb; 41(2): 170–5

    Article  PubMed  CAS  Google Scholar 

  42. Dixon R, Engleman K, Kemp J, et al. A comparison of the pharmacokinetics and tolerability of the novel antimigraine compound zolmitriptan in adolescents and adults. J Child Adolesc Psychopharmacol 1999; 9(1): 35–42

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

At the time of preparation of this manuscript, the authors were employed by Pharmacia, Inc., which had a co-marketing agreement with Almirall Prodesfarma, S.A., Barcelona, Spain.

Author information

Authors and Affiliations

  1. Clinical Pharmacology Unit, Pharmacia, Inc., Kalamazoo, Michigan, USA

    Janet D. McEnroe &  Joseph C. Fleishaker

Authors
  1. Janet D. McEnroe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph C. Fleishaker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph C. Fleishaker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McEnroe, J.D., Fleishaker, J.C. Clinical Pharmacokinetics of Almotriptan, a Serotonin 5-HT1B/1D Receptor Agonist for the Treatment of Migraine. Clin Pharmacokinet 44, 237–246 (2005). https://doi.org/10.2165/00003088-200544030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-200544030-00002

Keywords

Search

Navigation